Zacks Investment Research on MSN11h
BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track TagBiogen BIIB announced that the FDA has granted fast track designation to its investigational Alzheimer's disease (AD) drug, ...
Japan's Nikkei Stock Average closed 0.3% higher at 35725.87 as gains in the heavy industry and video game shares offset the ...
The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...
Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved ...
A European regulatory committee has rejected Eli Lilly's U.S.-approved Alzheimer's disease treatment over potentially ...
Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...
Eli Lilly, which is seeking European approval of Kisunla for the treatment of early symptomatic Alzheimer's, said it will seek re-examination by CHMP. The Indianapolis drugmaker said it remains ...
The European Medicines Agency committee declined to approve Eli Lilly's Alzheimer’s treatment, citing risks of brain bleeding ...
There are glimmers of hope, however, with Eisai reporting last month that it is on track to meet that fiscal 2024 sales ...
Although Eisai decided not to option a HER2-targeted drug under a deal with BlissBio, Angle wants to keep working with the firms to advance its CTC technology.
With the demonstration of the ability to measure HER2 circulating tumour cells status dynamically over time, Angle said it successfully completed its contract with Eisai. Separately, Angle said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback